Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-04

Study Completion Date

2021-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor.

Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days after the treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant

NCT00078533

Cytomegalovirus Infections

COMPLETED PHASE1

Alternate Donor Study of Pre-Emptive Cellular Therapy

NCT01220895

Cytomegalovirus Infection

COMPLETED PHASE2

CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

NCT03067155

Hematological Malignancies CMV Infection

COMPLETED PHASE2

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

NCT00711035

Adenovirus Infection EBV Infection

COMPLETED PHASE1/PHASE2

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613

Cancer

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, multicentre, open-label and uncontrolled phase Ib-II clinical trial in which a total of 20 patients ≥ 1 year of age with an allogeneic transplant of hematopoietic progenitors and post-transplant CMV infection will be included. The main objective is to evaluate the safety of the infusion of CMV activated T-lymphocytes and secondary objectives are to evaluate the efficacy through clinical evolution, viral load, ability to induce immunoreconstitution against the virus and evaluation of the persistence of specific T cells.

The treatment will be administered intravenously (central or peripheral route) in a single dose at a dose of 0.01-5 E4 specific virus T lymphocytes per Kg of receptor weight. After the infusion, patients will follow periodic controls (+7, +14, +21, +28, +45 and +60 days) in which a clinical evaluation will be performed and blood samples will be obtained in order to evaluate the persistence of specific T cells in the recipient:

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CMV Viremia Immunosuppression-related Infectious Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Activated T-Lymphocytes

Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.

Group Type EXPERIMENTAL

Activated T-Lymphocytes

Intervention Type DRUG

Activated T-Lymphocytes will be infused intravenously in a single-dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Activated T-Lymphocytes

Activated T-Lymphocytes will be infused intravenously in a single-dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Recipient of an allogeneic hematopoietic progenitors cell transplant (irrespectively of the donor source, donor type conditioning and underlying disease) that is beyond the day +30 of the procedure
2. Patient with post-transplant infection due to CMV refractory or resistant to optimal pharmacological treatment. Specifically, the patient must be included in any of the following cases

1. Patient with organic disease caused by CMV (confirmed by histology) resistant to antiviral first line treatment
2. Patient with CMV reactivation and no organic disease, resistant or intolerant to 2 previous antiviral treatment lines (ganciclovir/valganciclovir and foscarnet) or not candidate to be treated due to not acceptable expected toxicity (severe renal insufficiency, neutropenia or severe thrombopenia) It is agreed that the patient is affected with a resistant CMV infection if the CMV copies doesn't decrease in \> 1 log in total blood or otherwise the absolute number of copies \> 1x10E4/mL in total blood after 2 weeks of antiviral treatment.
3. Patients with reactivation of recurrent CMV despite correct anti-CMV treatment. It will be considered a recurrent CMV infection if the patient has \> 2 reactivations in a period \<6 months despite having received correct anti-CMV treatment
4. Documented genetic mutations associated with ganciclovir or foscarnet resistance
3. ≥ 1 year of age
4. Estimated life expectancy \> 30 days
5. Signature of the informed consent form

Exclusion Criteria

1. Acute graft-versus-host disease (GVHD) ≥ grade II or chronic ≥ moderate
2. Corticosteroid ≥ 0.5mg/kg regardless the indication
3. Disease relapse at the time of infection or at any time after the Allogeneic transplant.
4. Severe renal disease (creatinine \> 3gr/dL)
5. Severe hepatic disease (bilirubin \>3mg/dL or aspartate aminotransferase (AST) \>500 U/L) except if it is secondary to the viral infection.
6. Having received a donor lymphocytes infusion or any cell therapy product within 60 days prior to inclusion in the study (with the exception of transfusions), or having it planned within the next 60 days.
7. Alteration of the general condition, infection or clinical or hemodynamic instability that, in the opinion of the researcher, does not recommend the use of T cells
8. Known hypersensitivity to murine proteins or iron dextran.
9. Positive serology to human immunodeficiency virus (HIV), hepatitis B virus (HBV) (HBsAg, HBcAc), hepatitis C virus (HCV) and/or syphilis
10. Pregnant, lactating or women without adequate contraception
11. Participation in a clinical trial with investigational medicinal products the last 30 days

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No